Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain

被引:689
作者
Chessell, IP
Hatcher, JP
Bountra, C
Michel, AD
Hughes, JP
Green, P
Egerton, J
Murfin, M
Richardson, J
Peck, WL
Grahames, CBA
Casula, MA
Yiangou, Y
Birch, R
Anand, P
Buell, GN
机构
[1] GlaxoSmithKline, Pain Res, N&GI CEDD, Harlow CM19 5AW, Essex, England
[2] GlaxoSmithKline, NeuroCell Sci, Harlow CM19 5AW, Essex, England
[3] Glaxo Inst Appl Pharmacol, Cambridge CB2 5DH, England
[4] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Peripheral Neuropathy Unit, London W12 0NN, England
[5] Royal Natl Orthopaed Hosp, Peripheral Nerve Injury Unit, Stanmore HA7 4LP, Middx, England
[6] Glaxo Inst Mol Biol SA, CH-1228 Geneva, Switzerland
关键词
P2X(7); purinoceptor; interleukin; 1; beta; neuropathic; Taqman;
D O I
10.1016/j.pain.2005.01.002
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The P2X(7) purinoceptor is a ligand-gated cation channel, expressed predominantly by cells of immune origin, with a unique phenotype which includes release of biologically active inflammatory cytokine, interleukin (IL)-1 beta following activation, and unique ion channel biophysics observed only in this receptor family. Here we demonstrate that in mice lacking this receptor, inflammatory (in an adjuvant-induced model) and neuropathic (in a partial nerve ligation model) hypersensitivity is completely absent to both mechanical and thermal stimuli, whilst normal nociceptive processing is preserved. The knockout animals were unimpaired in their ability to produce mRNA for pro-IL-1 beta, and cytometric analysis of paw and systemic cytokines from knockout and wild-type animals following adjuvant insult suggests a selective effect of the gene deletion on release of IL-1 beta and IL-10, with systemic reductions in adjuvant-induced increases in IL-6 and MCP-1. In addition, we show that this receptor is upregulated in human dorsal root ganglia and injured nerves obtained from chronic neuropathic pain patients. We hypothesise that the P2X7 receptor, via regulation of mature IL-10 production, plays a common upstream transductional role in the development of pain of neuropathic and inflammatory origin. Drugs which block this target may have the potential to deliver broad-spectrum analgesia. (c) 2005 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:386 / 396
页数:11
相关论文
共 39 条
[1]   Novel P2X7 receptor antagonists [J].
Alcaraz, L ;
Baxter, A ;
Bent, J ;
Bowers, K ;
Braddock, M ;
Cladingboel, D ;
Donald, D ;
Fagura, M ;
Furber, M ;
Laurent, C ;
Lawson, M ;
Mortimore, M ;
McCormick, M ;
Roberts, N ;
Robertson, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (22) :4043-4046
[2]  
Aley KO, 1998, J NEUROSCI, V18, P7008
[3]  
Budziñski M, 1999, LIFE SCI, V66, P301
[4]   Blockade of human P2X7 receptor function with a monoclonal antibody [J].
Buell, G ;
Chessell, IP ;
Michel, AD ;
Colo, G ;
Salazzo, M ;
Herren, S ;
Gretener, D ;
Grahames, C ;
Kaur, R ;
Kosco-Vilbois, MH ;
Humphrey, PPA .
BLOOD, 1998, 92 (10) :3521-3528
[5]   Cloning and functional characterisation of the mouse P2X7 receptor [J].
Chessell, IP ;
Simon, J ;
Hibell, AD ;
Michel, AD ;
Barnard, EA ;
Humphrey, PPA .
FEBS LETTERS, 1998, 439 (1-2) :26-30
[6]   Chronic pain prevalence and analgesic prescribing in a general medical population [J].
Clark, JD .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (02) :131-137
[7]  
Clayton NM, 1997, BRIT J PHARMACOL, V120, pP219
[8]   Tissue distribution of the P2X(7) receptor [J].
Collo, G ;
Neidhart, S ;
Kawashima, E ;
KoscoVilbois, M ;
North, RA ;
Buell, G .
NEUROPHARMACOLOGY, 1997, 36 (09) :1277-1283
[9]   Maturation and release of interleukin-1β by lipopolysaccharide-primed mouse Schwann cells require the stimulation of P2X7 receptors [J].
Colomar, A ;
Marty, V ;
Médina, C ;
Combe, C ;
Parnet, P ;
Amédée, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (33) :30732-30740
[10]   INACTIVATION IN-VIVO OF METABOTROPIC GLUTAMATE-RECEPTOR-1 BY SPECIFIC CHROMOSOMAL INSERTION OF REPORTER GENE LACZ [J].
CONQUET, F .
NEUROPHARMACOLOGY, 1995, 34 (08) :865-870